August 8, 2020

The Niche

Knoepfler lab stem cell blog

STEM stock

2 min read

A sad, but not surprising day for the stem cell field as the biotech StemCells, Inc. announced that it is winding down its operations after terminating its spinal cord injury trial called the Pathway Study. The data generated so far did not justify continuing the trial. StemCells, Inc. (stock symbol STEM) has struggled financially for quite some time. In February of this year I asked if the company could cheat death given how bad things were looking and what I was hearing through the …Read More

1 min read

California stem cell biotech, StemCells, Inc. ($STEM), has really struggled for years and its stock is now flatlining raising the question: can it cheat death? Will 2016 be the year that STEM turns things around? So far this year hasn’t started off that well. You can see the graph at right from today on the STEM stock price. Ron Leuty over at San Francisco Business Times reported a couple of weeks ago on a juicy severance package for departing STEM CEO Marty McGlynn despite …Read More

1 min read

I’ve added a fun and helpful new feature on the right side bar of the blog in the form of a stem cell biotech stock ticker. The ticker is for some of the most widely held stem and cellular medicine companies. A sample screen shot is shown in this post. Quite a few stem cell-related stocks could not be added to this ticker for various reasons including ACTC, Mesoblast, CUR, and others. Yahoo has limits on which stocks can be included based on company …Read More